@article{29418,
  keywords = {Animals, Antibodies, Chorionic Gonadotropin, Clinical Trials, Phase II as Topic, Contraceptive Agents, Female, Female, Humans, Immunologic Factors, Mice, Mice, Inbred C3H, Mycobacterium, Vaccines, Synthetic},
  author = {Purswani S and Talwar G P and Vohra R and Pal R and Panda A and Lohiya NK and Gupta JC},
  title = {Mycobacterium indicus pranii is a potent immunomodulator for a recombinant vaccine against human chorionic gonadotropin.},
  abstract = {<p>The objective of this work was to identify a human use-permissible adjuvant to enhance significantly the antibody response to a recombinant anti-hCG vaccine. Previous Phase II efficacy trials in sexually active women have demonstrated the prevention of pregnancy at hCG bioneutralization titers of 50ng/ml or more. Mycobacterium indicus pranii (MIP), a non-pathogenic Mycobacterium employed as an autoclaved suspension in aqueous buffer, significantly increased antibody titers in the FVB strain of mice. Three other genetic strains of mice: SJL, C3H, and C57Bl/6 responded with antibody titers several-fold higher than 50 ng/ml, which is the protective threshold in women, although there were differences in the peak titers attained. In addition, the duration of the antibody response was lengthened. The vaccine hCGβ-LTB, given together with MIP, induces both a Th1 and Th2 response, which is reflected in the production of not only IgG1, but also a high proportion of IgG2a and IgG2b antibodies.</p>
},
  year = {2011},
  journal = {Journal of reproductive immunology},
  volume = {91},
  pages = {24-30},
  issn = {1872-7603},
  doi = {10.1016/j.jri.2011.06.099},
  language = {eng},
}